Close Menu

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Thermo Fisher will acquire PPD for $47.50 per share for a total price of $17.4 billion, plus the assumption of approximately $3.5 billion in debt.

Pure Biologics will pay technology access fees for Twist's antibody phage display libraries and milestones payments for any antibodies developed.

At the AACR Annual Meeting, Sharpless said NCI should focus on improving early screening, access to trials, and development of advanced drugs to realize President Biden's goal of eradicating cancer.

The two firms will use their sequencing and informatics technologies to develop personalized cancer vaccines targeting patients' unique neoantigens.

Gresham House Ventures led the investment in Cambridge, UK-based Metrion Biosciences, which specializes in ion channel contract research and drug discovery.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.

Sponsored by

This webinar will discuss a study that sought to identify early biomarkers for cancer by analyzing pre-diagnosis samples from seemingly healthy individuals who were later diagnosed with cancer.

Sponsored by

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Sponsored by
Akoya Biosciences

Single-cell omics assays have become essential tools for identifying and characterizing cell types and states of complex tissues. While each single-modality assay reveals distinctive features about the sequenced cells, true multiomics assays are still in the early stage of development. 

Sponsored by
Akoya Biosciences

Recently developed technologies for digital imaging and highly multiplexed immunohistochemistry (mIHC) advancing the field of histology into a quantitative era, allowing for more complex descriptions of tissue architecture.